Atle Fund Management AB
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed July 24, 2026), Atle Fund Management AB reported 39 stock positions worth $371.7 million. Its top holding was Eli Lilly (LLY) at 9.6% of the portfolio, followed by Merck (MRK, 6.5%) and Johnson & Johnson (JNJ, 5.8%). Compared with Q1 2026, it opened 3 new positions, sold out of 3, added to 16 and reduced 20. The biggest buy was a new position in Biogen (BIIB) and the biggest sale an exit from Amgen (AMGN).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $371.7M (Q2 2026)
- SEC Filing
- 0001381843-26-000005 ↗ filed Jul 24, 2026
Holdings Value
Holdings 39 stocks · $371.7M
| LLY Eli Lilly & Co. | 9.62% | 29,821 | $35.8M | Reduce -24.9% |
| MRK Merck & Co. Inc. | 6.55% | 189,357 | $24.3M | Add +459.4% |
| JNJ Johnson & Johnson | 5.84% | 85,425 | $21.7M | Reduce -7.5% |
| ABBV Abbvie Inc. | 4.35% | 64,325 | $16.2M | Reduce -40.5% |
| CVS CVS Health Corp. | 4.07% | 146,102 | $15.1M | Add +514.6% |
| TMO Thermo Fisher Scientific Inc. | 3.76% | 27,859 | $14.0M | Add +21.2% |
| RVMD Revolution Medicines Inc. | 3.68% | 73,077 | $13.7M | Reduce -88.2% |
| BIIB Biogen Inc. | 3.65% | 62,781 | $13.6M | New |
| NBIX Neurocrine Biosciences Inc. | 3.31% | 72,898 | $12.3M | Reduce -18.7% |
| MIRM Mirum Pharmaceuticals Inc. | 3.17% | 100,807 | $11.8M | Reduce -48.5% |
| ALKS Alkermes PLC | 3.01% | 213,329 | $11.2M | Reduce -12.0% |
| IONS Ionis Pharmaceuticals Inc. | 2.93% | 137,131 | $10.9M | Add +392.0% |
| ONC Beone Medicines Ltd.-ADR | 2.70% | 35,180 | $10.0M | Reduce -15.7% |
| ISRG Intuitive Surgical Inc. | 2.64% | 24,656 | $9.8M | Reduce -65.2% |
| SYK Stryker Corp. | 2.56% | 30,283 | $9.5M | Add +12.8% |
| VRTX Vertex Pharmaceuticals Inc. | 2.56% | 19,131 | $9.5M | Reduce -16.8% |
| EW Edwards Lifesciences Corp. | 2.51% | 103,230 | $9.3M | Reduce -3.1% |
| BBIO Bridgebio Pharma Inc. | 2.50% | 124,707 | $9.3M | Add +12.0% |
| KRYS Krystal Biotech Inc. | 2.40% | 24,019 | $8.9M | Reduce -36.1% |
| COR Cencora Inc. | 2.37% | 31,126 | $8.8M | Add +32.6% |
| NAMS Newamsterdam Pharma Co. NV | 2.27% | 248,848 | $8.4M | Add +162.5% |
| ABVX Abivax SA-ADR | 2.09% | 58,170 | $7.8M | Add +84.1% |
| INCY Incyte Corp. | 1.74% | 56,953 | $6.5M | Add +12.1% |
| IRTC Irhythm Holdings Inc. | 1.73% | 54,102 | $6.4M | Add +142.4% |
| BSX Boston Scientific Corp. | 1.68% | 146,381 | $6.2M | Add +262.0% |
| INSM Insmed Inc. | 1.67% | 58,378 | $6.2M | Reduce -40.1% |
| TNGX Tango Therapeutics Inc. | 1.67% | 198,557 | $6.2M | Add +563.7% |
| GILD Gilead Sciences Inc. | 1.57% | 46,142 | $5.8M | Reduce -3.8% |
| CAH Cardinal Health Inc. | 1.51% | 23,630 | $5.6M | Reduce -78.3% |
| ORKA Oruka Therapeutics Inc. | 1.41% | 54,886 | $5.2M | New |
| SYRE Spyre Therapeutics Inc. | 1.36% | 57,030 | $5.1M | Reduce -9.1% |
| DXCM Dexcom Inc. | 1.30% | 71,846 | $4.8M | Reduce -87.7% |
| BCAX Bicara Therapeutics Inc. | 1.16% | 145,657 | $4.3M | Reduce -87.5% |
| IDYA Ideaya Biosciences Inc. | 0.95% | 94,478 | $3.5M | Add +203.5% |
| CELC Celcuity Inc. | 0.94% | 33,313 | $3.5M | Reduce -76.4% |
| IRON Disc Medicine Inc. | 0.86% | 43,682 | $3.2M | Reduce -59.3% |
| PYXS Pyxis Oncology Inc. | 0.78% | 966,459 | $2.9M | Add +390.5% |
| CMPX Compass Therapeutics Inc. | 0.62% | 1,048,593 | $2.3M | Add +2406.7% |
| JBIO Jade Biosciences Inc. | 0.53% | 88,556 | $2.0M | New |
Portfolio Sells Q1 2026 → Q2 2026
| AMGN Amgen Inc. | Sold out | 0.00% | −2.81 |
| ONC Beone Medicines Ltd.-ADR | Reduce -15.7% | 2.70% | −1.22 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -16.8% | 2.56% | −1.05 |
| UNH Unitedhealth Group Inc. | Sold out | 0.00% | −0.90 |
| GILD Gilead Sciences Inc. | Reduce -3.8% | 1.57% | −0.74 |
| CELC Celcuity Inc. | Reduce -76.4% | 0.94% | −0.72 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.71 |
| ISRG Intuitive Surgical Inc. | Reduce -65.2% | 2.64% | −0.41 |
| INSM Insmed Inc. | Reduce -40.1% | 1.67% | −0.25 |
| IRON Disc Medicine Inc. | Reduce -59.3% | 0.86% | −0.17 |
| EW Edwards Lifesciences Corp. | Reduce -3.1% | 2.51% | −0.16 |
| CAH Cardinal Health Inc. | Reduce -78.3% | 1.51% | −0.03 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -48.5% | 3.17% | +0.14 |
| KRYS Krystal Biotech Inc. | Reduce -36.1% | 2.40% | +0.21 |
| SYRE Spyre Therapeutics Inc. | Reduce -9.1% | 1.36% | +0.24 |
| ALKS Alkermes PLC | Reduce -12.0% | 3.01% | +0.35 |
| BCAX Bicara Therapeutics Inc. | Reduce -87.5% | 1.16% | +0.42 |
| DXCM Dexcom Inc. | Reduce -87.7% | 1.30% | +0.45 |
| RVMD Revolution Medicines Inc. | Reduce -88.2% | 3.68% | +0.75 |
| NBIX Neurocrine Biosciences Inc. | Reduce -18.7% | 3.31% | +0.77 |
| LLY Eli Lilly & Co. | Reduce -24.9% | 9.62% | +0.95 |
| ABBV Abbvie Inc. | Reduce -40.5% | 4.35% | +1.00 |
| JNJ Johnson & Johnson | Reduce -7.5% | 5.84% | +1.98 |
Portfolio Buys Q1 2026 → Q2 2026
| BIIB Biogen Inc. | New | 3.65% | +3.65 |
| ORKA Oruka Therapeutics Inc. | New | 1.41% | +1.41 |
| CVS CVS Health Corp. | Add +514.6% | 4.07% | +1.07 |
| ABVX Abivax SA-ADR | Add +84.1% | 2.09% | +0.54 |
| JBIO Jade Biosciences Inc. | New | 0.53% | +0.53 |
| TNGX Tango Therapeutics Inc. | Add +563.7% | 1.67% | +0.50 |
| NAMS Newamsterdam Pharma Co. NV | Add +162.5% | 2.27% | +0.49 |
| PYXS Pyxis Oncology Inc. | Add +390.5% | 0.78% | +0.26 |
| COR Cencora Inc. | Add +32.6% | 2.37% | +0.24 |
| IONS Ionis Pharmaceuticals Inc. | Add +392.0% | 2.93% | −0.11 |
| IRTC Irhythm Holdings Inc. | Add +142.4% | 1.73% | −0.29 |
| IDYA Ideaya Biosciences Inc. | Add +203.5% | 0.95% | −0.35 |
| CMPX Compass Therapeutics Inc. | Add +2406.7% | 0.62% | −0.37 |
| SYK Stryker Corp. | Add +12.8% | 2.56% | −0.53 |
| INCY Incyte Corp. | Add +12.1% | 1.74% | −0.84 |
| MRK Merck & Co. Inc. | Add +459.4% | 6.55% | −0.85 |
| TMO Thermo Fisher Scientific Inc. | Add +21.2% | 3.76% | −0.91 |
| BSX Boston Scientific Corp. | Add +262.0% | 1.68% | −1.18 |
| BBIO Bridgebio Pharma Inc. | Add +12.0% | 2.50% | −1.34 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |